[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.168.204. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correction
July 2003

Clozapine Treatment for Suicidality in Schizophrenia—Correction

Arch Gen Psychiatry. 2003;60(7):735. doi:10.1001/archpsyc.60.7.735

Errors in Text and Table. In the Original Article by Meltzer et al titled “Clozapine Treatment for Suicidality in Schizophrenia: International Suicide Prevention Trial (InterSePT),” published in the January issue of the ARCHIVES (2003;60:82-91), the following errors occurred in the text and in a table: On page 83, right column, last paragraph, the first sentence should have read as follows: “Every potential type 1 end point (see the ‘Outcome Definitions’ subsection) was reviewed by all of the members of the SMB, and consensus was obtained.” On page 84, right column, last paragraph, the second sentence (continuing to page 85) should have read as follows: “Putative explanatory variables, that is, factors that may have contributed to the primary end point in this model, included treatment, number of previous suicide attempts, active substance or alcohol abuse, pooled country, medical center, sex, and age group (18-32, 33-44, and ≥45 years) at baseline.” On page 86, in Table 4, for the sideheading “Concomitant medications” and the subheading “Antidepressants,” the number (percentage) for the clozapine group should have read “221(46.1),” and for the olanzapine group, “258 (54.1).” In that same table, for the sideheading “Concomitant medications” and the subheading “Anxiolytics/soporifics,” the number (percentage) for the clozapine group should have read “301 (62.8),” and the P value (95% confidence interval [CI] of the difference) (olanzapine minus clozapine) should have read “.03 (.01 to .13).” On page 87, left column, last paragraph, the third sentence should have read as follows: “On the other hand, when suicide attempts were rated for probability of success by the principal investigator, a ‘high probability for success’ of a completed suicide was found for 8 events in the clozapine group and 14 events in the olanzapine group.” Also on page 87, right column, second paragraph, the third and fourth sentences should have read as follows: “The time in days to observe the first 70 patients with type 1 events was 185 days for the clozapine-treated patients and 126 days for the olanzapine-treated patients. A significant reduction in the 2-year event rate at the end of the study (olanzapine, 32.2% vs clozapine, 24.0%; 95% CI of the difference, 0.02-0.14; number needed to treat, 13) and a delay in time to event were demonstrated for clozapine-treated patients.” The last sentence in that same paragraph should have read as follows: “The overall annualized rate for attempted suicides (including suicide deaths) was 7.2%, with a rate of 8.7% for olanzapine-treated patients and 5.8% for clozapine-treated patients.” On page 88, left column, second paragraph, the first and second sentences should have read as follows: “Comparison of the overall use of concomitant medications for any reason, not only suicidality, shows that antidepressants were used more frequently in patients treated with olanzapine (54.1%) than in those treated with clozapine (46.1%) (P=.01) (Table 4). Anxiolytics and soporifics were also used more frequently in patients treated with olanzapine(69.4%) than in those treated with clozapine (62.8%) (P=.03).” Also on page 88, right column, in the “Comment” section, second paragraph, the first sentence should have read as follows: “Although the total number of suicide-related deaths was greater in the clozapine-treated group, this was not significant and, as indicated already, the study was not powered to evaluate this as an end point.” Finally, on page 90, right column, second paragraph, the third sentence should have read as follows: “The InterSePT indicates that, on average, treatment of only 13 patients with clozapine rather than olanzapine will show benefit for clozapine to reduce suicidal behavior.”

First Page Preview View Large
First page PDF preview
First page PDF preview
×